| RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies. J Wang, Y Liu, Q Zhang, J Feng, J Fang, X Chen, Y Han, Q Li, P Zhang, ... Journal of Clinical Oncology 39 (15_suppl), 1022-1022, 2021 | 86 | 2021 |
| Clinicopathological characteristics and prognosis of breast cancer with special histological types: a surveillance, epidemiology, and end results database analysis Y Han, J Wang, B Xu The Breast 54, 114-120, 2020 | 46 | 2020 |
| Clinicopathological characteristics and prognosis of HER2-low early-stage breast cancer: a single-institution experience H Xu, Y Han, Y Wu, Y Wang, Q Li, P Zhang, P Yuan, Y Luo, Y Fan, S Chen, ... Frontiers in oncology 12, 906011, 2022 | 38 | 2022 |
| Abstract PD4-06: Early clinical development of RC48-ADC in patients with HER2 positive metastatic breast cancer B Xu, J Wang, J Fang, X Chen, Y Han, Q Li, P Zhang, P Yuan, F Ma, Y Luo, ... Cancer Research 80 (4_Supplement), PD4-06-PD4-06, 2020 | 26 | 2020 |
| Profile and outcome of receptor conversion in breast cancer metastases: a nation‐wide multicenter epidemiological study ZB Yi, P Yu, S Zhang, WN Wang, YQ Han, QC Ouyang, M Yan, XJ Wang, ... International Journal of Cancer 148 (3), 692-701, 2021 | 17 | 2021 |
| Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and … Y Han, J Wang, Z Wang, B Xu Current Problems in Cancer 44 (6), 100606, 2020 | 13 | 2020 |
| Cutaneous adverse events associated with immune checkpoint blockade: a systematic review and meta-analysis Y Han, J Wang, B Xu Critical Reviews in Oncology/Hematology 163, 103376, 2021 | 11 | 2021 |
| Prognostic model and nomogram for estimating survival of small breast cancer: A SEER-based analysis Y Han, J Wang, Y Sun, P Yu, P Yuan, F Ma, Y Fan, Y Luo, P Zhang, Q Li, ... Clinical Breast Cancer 21 (5), e497-e505, 2021 | 10 | 2021 |
| Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer Y Han, J Wang, B Xu Journal of Cancer 12 (3), 936, 2021 | 9 | 2021 |
| Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis Y Han, J Wang, W Liu, P Yuan, Q Li, P Zhang, F Ma, Y Luo, Y Fan, S Chen, ... Cancer Management and Research, 4699-4706, 2019 | 9 | 2019 |
| The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study Y Han, Y Wu, H Xu, J Wang, B Xu International Journal of Clinical Oncology 27 (4), 707-716, 2022 | 8 | 2022 |
| CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta … H Xu, Y Wang, Y Han, Y Wu, J Wang, B Xu Frontiers in Oncology 12, 956464, 2022 | 7 | 2022 |
| A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer. J Wang, B Xu, T Sun, Q Ouyang, Y Han, Q Li, P Zhang, F Ma, Y Luo, ... Journal of Clinical Oncology 39 (15_suppl), 1074-1074, 2021 | 6 | 2021 |
| Efficacy and safety of bevacizumab in pretreated metastatic breast cancer: a systematic review and meta-analysis Z Li, F Guo, Y Han, J Wang, B Xu Oncology Research and Treatment 45 (10), 608-617, 2022 | 5 | 2022 |
| Comparative efficacy of tyrosine kinase inhibitors and antibody–drug conjugates in HER2-positive metastatic breast cancer patients with brain metastases: a systematic review … Y Wang, H Xu, Y Han, Y Wu, J Wang Cancers 14 (14), 3372, 2022 | 5 | 2022 |
| Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer Y Wu, Y Han, Q Li, P Zhang, P Yuan, Y Luo, Y Fan, S Chen, R Cai, Q Li, ... Breast Cancer Research and Treatment 193 (2), 381-392, 2022 | 5 | 2022 |
| Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation‐wide multicenter study F Guo, Z Yi, W Wang, Y Han, P Yu, S Zhang, Q Ouyang, M Yan, X Wang, ... Cancer Medicine 10 (19), 6744-6761, 2021 | 5 | 2021 |
| A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer J Wang, T Sun, Q Ouyang, Y Han, B Xu Iscience 26 (6), 2023 | 4 | 2023 |
| Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis Y Wang, H Xu, Y Han, Y Wu, Q Sa, J Wang ESMO open 8 (3), 101216, 2023 | 4 | 2023 |
| Endocrine therapy-based strategies for metastatic breast cancer with different endocrine sensitivity statuses: A systematic review and network meta-analysis J Wang, Y Han, J Wang, Q Li, B Xu Cancers 14 (24), 6100, 2022 | 4 | 2022 |
